Business
Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the U.S. Department of Defense (DoD) has awarded a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI). This funding builds on Tiziana’
About this update from Tiziana Life Sciences Ltd
[{"type":"image","alt":"Tiziana Life Sciences Ltd.","displaySize":"","headline":null,"caption":"Tiziana Life Sciences Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":264,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/08f5d705b5df39888a6496fd7522f947"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3k64r3yQgq2ENSiAhwIMCA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/08f5d705b5df39888a6496fd7522f947","width":264,"height":60}},"lazy":false},{"type":"text","content":"BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the U.S. Department of Defense (DoD) has awarded a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI). This funding builds on Tiziana’s strategy to expand the therapeutic potential of its intranasal anti-CD3 platform beyond autoimmune and neuroinflammatory diseases into large, underserved neurological indications.","length":681,"tagName":"p"},{"type":"text","content":"The DoD award will support a three-year study of intranasal anti-CD3 in the acute phase of SCI, aimed at patients who present to the hospital immediately following injury. Complementing this, a two-year Stepping Strong Breakthrough Award will expand research into the chronic phase, focusing on patients living with persistent neurological deficits.","length":349,"tagName":"p"},{"type":"text","content":"Traumatic SCI is a major unmet medical need, with nearly 300,000 Americans living with permanent disability and more than 17,000 new injuries annually. Current standard of care remains supportive, with no approved therapies that improve neurological recovery or prevent the chronic complications caused by persistent spinal cord inflammation. The Company believes this represents a significant commercial opportunity in a market with high disease burden and no disease-modifying treatments.","length":490,"tagName":"p"},{"type":"text","content":"Researchers in the Immunology of CNS Injury Program at Brigham and Women’s Hospital, a founding member of Mass General Brigham, have previou...